Home › Funds › Propel Bio Management, LLC › CABA
Propel Bio Management, LLC position in CABA
CABALETTA BIO INC · Health Care
Propel Bio Management, LLC reported holding 2,049,471 shares of CABA (CABALETTA BIO INC) in its Q3 2026 13F filing — a position valued at US$3.9M, representing 2.09% of its reported portfolio and ranking #16 among its reported holdings. Propel Bio Management, LLC first reported this position in Q3 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's CABA position evolved
Propel Bio Management, LLC first disclosed a stake in CABA in Q3 2026 at 2,049,471 shares (US$3.9M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 2.05M | $3.93M | New |
About CABA and 13F data
CABA (CABALETTA BIO INC) is a Health Care company. 35 other funds we track also report a position in CABA — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$53.6M), Cormorant Asset Management, LP (US$15.6M), Opaleye Management Inc. (US$12.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CABA
- Bain Capital Life Sciences Investors, LLC 17.24M sh · $53.62M · Q2 2026
- Cormorant Asset Management, LP 5.00M sh · $15.55M · Q2 2026
- Opaleye Management Inc. 3.86M sh · $12.02M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 1.28M sh · $3.48M · Q2 2026
- Stonepine Capital Management, LLC 917.10K sh · $2.85M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held CABA?
Propel Bio Management, LLC has disclosed CABA holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Propel Bio Management, LLC's current position in CABA?
As of Q3 2026, Propel Bio Management, LLC holds 2.05M shares of CABA (CABALETTA BIO INC), valued at $3.93M, representing 2.09% of its reported portfolio and ranking #16.
Has Propel Bio Management, LLC been buying or selling CABA?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC newly opened its position in CABA.
Which other funds hold CABA?
Other major institutional holders of CABA include Bain Capital Life Sciences Investors, LLC, Cormorant Asset Management, LP, Opaleye Management Inc., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.